Market LIVE
Published markets; coverage varies by country
Product profile · United States

BRENZAVVY

 ·  Patent Litigation & Settlement History ↓

IngredientBEXAGLIFLOZIN
Application typeNDA
Application214373
Product001
Dosage formTABLET
RouteORAL
Strength20MG
Approval date2023-01-20
Marketing statusPrescription
Status event—
ApplicantTHERACOSBIO
Product source

Current GenericRadar decision

Year2029
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeTRUE_DS_PATENT
Anchor date2029-01-30
Patent anchor2029-01-30
Exclusivity anchor2028-01-20
Protection date2041-10-05
First Final ANDA—
Status event—

POST_ANCHOR_RIGHTS_EXIST; US:NDA:214373:001; exact Final ANDA not verified; not proof of generic absence

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
81060212028-08-22U U-2214NYU
| B1C03P7 issued-claim review2026-10-15: U
———
81060212028-08-22ORANGE_BOOK U-2214NYU
English description not available.
———
88026372028-08-22DS/DP/U U-2214YNTRUE_DS
| B1C03P7 issued-claim review2026-10-15: TRUE_DS
———
88026372028-08-22ORANGE_BOOK U-2214YNTRUE_DS
English description not available.
———
78384992029-01-30DS/DP/U U-2214YNTRUE_DS
| B1C03P7 issued-claim review2026-10-15: TRUE_DS
———
78384992029-01-30ORANGE_BOOK U-2214YNTRUE_DS
English description not available.
———
109819422031-06-13DS/DP —NNDP
| B1C03P7 issued-claim review2026-10-15: DP
———
109819422031-06-13ORANGE_BOOK —NNDP
English description not available.
———
105330322031-07-03U U-2214NNU
| B1C03P7 issued-claim review2026-10-15: U
———
105330322031-07-03ORANGE_BOOK U-2214NNU
English description not available.
———
89873232032-05-14DS/DP —NNDP
| B1C03P7 issued-claim review2026-10-15: DP
———
89873232032-05-14ORANGE_BOOK —NNDP
English description not available.
———
125942432041-10-05DP —NNDP
| B1C03P7 issued-claim review2026-10-15: DP
———
125942432041-10-05ORANGE_BOOK —NNDP
English description not available.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE2023-01-202028-01-20English description not available.YY2028-01-20—Source
NCE2023-01-202028-01-20English description not available.YY2028-01-20
NCE
Full coverage date: 2028-01-20
Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (9)
TypeDateRoleBasisSource
PATENT2028-08-22HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2028-08-22HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2029-01-30CANONICAL_ANCHOREnglish description not available.Source
PATENT2031-06-13FTO_TAILEnglish description not available.Source
PATENT2031-07-03FTO_TAILEnglish description not available.Source
PATENT2032-05-14FTO_TAILEnglish description not available.Source
PATENT2041-10-05FTO_TAILEnglish description not available.Source
REGULATORY_EXCLUSIVITY—REGULATORY_SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_STATUS2029-01-30CANONICAL_DECISIONPOST_ANCHOR_RIGHTS_EXIST; US:NDA:214373:001; exact Final ANDA not verified; not proof of generic absenceSource
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.